Type 2 Diabetes – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Type 2 Diabetes – Pipeline Review, H1 2017’, provides an overview of the Type 2 Diabetes pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Type 2 Diabetes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Type 2 Diabetes

– The report reviews pipeline therapeutics for Type 2 Diabetes by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Type 2 Diabetes therapeutics and enlists all their major and minor projects

– The report assesses Type 2 Diabetes therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Type 2 Diabetes

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4P Therapeutics LLC

Addex Therapeutics Ltd

Adocia

Advinus Therapeutics Ltd

Aegis Therapeutics LLC

AFFiRiS AG

Alize Pharma SAS

Allergan Plc

Alteogen Inc

Amarantus Bioscience Holdings Inc

Amgen Inc

Anchor Therapeutics Inc

AntriaBio Inc

Aphios Corp

Araim Pharmaceuticals Inc

Arena Pharmaceuticals Inc

Arisaph Pharmaceuticals Inc

ArisGen SA

Astellas Pharma Inc

AstraZeneca Plc

AusBio Ltd

Avadel Pharmaceuticals Plc

Bayer AG

Beta-Cell NV

Betagenon AB

Betta Pharmaceuticals Co Ltd

Biocon Ltd

BioLingus AG

BioRestorative Therapies Inc

Biozeus

Biscayne Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Boston Therapeutics Inc

Braasch Biotech LLC

Bristol-Myers Squibb Company

C4X Discovery Holdings PLC

Cadila Pharmaceuticals Ltd

Cardax Inc

Carmot Therapeutics Inc

Celon Pharma SA

Chipscreen Biosciences Ltd

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

CohBar Inc

Concenter BioPharma Silkim Ltd

ConjuChem LLC

Connexios Life Sciences Pvt Ltd

ConSynance Therapeutics Inc

Corium International Inc

CSL Ltd

CureDM Inc

CymaBay Therapeutics Inc

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Company Ltd

Dance Biopharm Inc

Delpor Inc

Diabetology (Products) Ltd

DiaMedica Therapeutics Inc

Diamyd Medical AB

Diasome Pharmaceuticals Inc

DiscoveryBiomed Inc

DNJ Pharma Inc

Dong-A Socio Holdings Co Ltd

Elcelyx Therapeutics Inc

Eli Lilly and Company

Enteris BioPharma Inc

Enzo Biochem Inc

Epichem Pty Ltd

Esperion Therapeutics Inc

Eternygen GmbH

Evotec AG

F. Hoffmann-La Roche Ltd

Generex Biotechnology Corp

Genexine Inc

Genfit SA

Genmedica Therapeutics SL

Genovate Biotechnology Co LTD

Geropharm LLC

Gilead Sciences Inc

GlaxoSmithKline Plc

Glide Pharmaceutical Technologies Ltd

Glucox Biotech AB

GW Pharmaceuticals Plc

Hadasit Medical Research Services & Development Ltd

HanAll Biopharma Co Ltd

Hanmi Pharmaceuticals Co Ltd

Heptares Therapeutics Ltd

HitGen LTD

Hyundai Pharmaceutical Co Ltd

Immuron Ltd

Innopharmax Inc

Innovative Targeting Solutions Inc

Intarcia Therapeutics Inc

Intas Pharmaceuticals Ltd

Integral Molecular Inc

Intercept Pharmaceuticals Inc

Intrexon Corp

Ionis Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Islet Sciences Inc

Japan Tobacco Inc

Jeil Pharmaceutical Co Ltd

Jenrin Discovery Inc

JHL Biotech Inc

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Kadimastem Ltd

Kadmon Corp LLC

Kareus Therapeutics SA

Kissei Pharmaceutical Co Ltd

Lead Discovery Center GmbH

Leading BioSciences Inc

Lexicon Pharmaceuticals Inc

LG Chem, Ltd.

Ligand Pharmaceuticals Inc

LipimetiX Development Inc

Lonestar Heart Inc

Longevity Biotech Inc

Luye Pharma Group Ltd

Magnus Life Ltd

Medesis Pharma SA

Medestea Research & Production SpA

MedImmune LLC

Medlab Clinical Ltd

Melior Discovery Inc

Mellitech SAS

Merck & Co Inc

Mesoblast Ltd

Metabolic Solutions Development Company LLC

Metabolys SAS

Metacrine Inc

Mitsubishi Tanabe Pharma Corp

Moderna Therapeutics Inc

Naia Ltd

Neurimmune Holding AG

Neurocrine Biosciences Inc

NGM Biopharmaceuticals Inc

Nordic Bioscience A/S

Novapeutics LLC

Novartis AG

NovaTarg Therapeutics Inc

Novo Nordisk A/S

Noxxon Pharma AG

Omeros Corp

OPKO Biologics Ltd

OPKO Health Inc

Oramed Pharmaceuticals Inc

Paras Biopharmaceuticals Finland Oy

Peptron Inc

Pfizer Inc

PharmaCyte Biotech Inc

PharmaIN Corp

Pila Pharma AB

Poxel SA

Prometheon Pharma LLC

ProMetic Life Sciences Inc

Purzer Pharmaceutical Co Ltd

Reata Pharmaceuticals Inc

ReCyte Therapeutics Inc

reMYND NV

Renova Therapeutics Inc

Reset Therapeutics Inc

Saniona AB

Sanofi

Sanwa Kagaku Kenkyusho Co Ltd

SATT Conectus Alsace SAS

SBI Pharmaceuticals Co Ltd

Seres Therapeutics Inc

Serodus ASA

Serometrix LLC

Sevion Therapeutics Inc

Shenzhen HighTide Biopharmaceutical Ltd

Shionogi & Co Ltd

Sihuan Pharmaceutical Holdings Group Ltd

Sirona Biochem Corp

SJT Molecular Research SL

SK Chemicals Co Ltd

Sprint Bioscience AB

Sumitomo Dainippon Pharma Co Ltd

Taisho Pharmaceutical Holdings Co Ltd

Takeda Pharmaceutical Company Ltd

Tasly Pharmaceutical Group Co Ltd

Teijin Pharma Ltd

The Medicines Company

Theracos Inc

Thermalin Diabetes LLC

Toray Industries Inc

Torrent Pharmaceuticals Ltd

Transgene Biotek Ltd

TTY Biopharm Company Ltd

Uni-Bio Science Group Ltd

Valeant Pharmaceuticals International Inc

ViaCyte Inc

Vichem Chemie Research Ltd

Vicore Pharma AB

Viking Therapeutics Inc

Vivus Inc

vTv Therapeutics Inc

Vybion Inc

XBiotech Inc

Xenetic Biosciences Inc

XL-protein GmbH

XOMA Corp

XuanZhu Pharma Co Ltd

Yuhan Corp

Yungjin Pharm Co Ltd

Zafgen Inc

Zealand Pharma AS

Zensun (Shanghai) Sci & Tech Co Ltd

Zydus Cadila Healthcare Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 11

Type 2 Diabetes Overview 12

Type 2 Diabetes Therapeutics Development 13

Type 2 Diabetes Therapeutics Assessment 67

Type 2 Diabetes Companies Involved in Therapeutics Development 89

Type 2 Diabetes Drug Profiles 198

Type 2 Diabetes Dormant Projects 997

Type 2 Diabetes Discontinued Products 1025

Type 2 Diabetes Product Development Milestones 1035

Appendix 1043

List of Tables

List of Tables

Number of Products under Development for Type 2 Diabetes, H1 2017 69

Number of Products under Development by Companies, H1 2017 71

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 72

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 73

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 74

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 75

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 76

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017 77

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017 78

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017 79

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017 80

Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017 81

Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017 82

Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017 83

Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017 84

Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017 85

Number of Products under Development by Universities/Institutes, H1 2017 86

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 88

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 89

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017 90

Products under Development by Companies, H1 2017 91

Products under Development by Companies, H1 2017 (Contd..1), H1 2017 92

Products under Development by Companies, H1 2017 (Contd..2), H1 2017 93

Products under Development by Companies, H1 2017 (Contd..3), H1 2017 94

Products under Development by Companies, H1 2017 (Contd..4), H1 2017 95

Products under Development by Companies, H1 2017 (Contd..5), H1 2017 96

Products under Development by Companies, H1 2017 (Contd..6), H1 2017 97

Products under Development by Companies, H1 2017 (Contd..7), H1 2017 98

Products under Development by Companies, H1 2017 (Contd..8), H1 2017 99

Products under Development by Companies, H1 2017 (Contd..9), H1 2017 100

Products under Development by Companies, H1 2017 (Contd..10), H1 2017 101

Products under Development by Companies, H1 2017 (Contd..11), H1 2017 102

Products under Development by Companies, H1 2017 (Contd..12), H1 2017 103

Products under Development by Companies, H1 2017 (Contd..13), H1 2017 104

Products under Development by Companies, H1 2017 (Contd..14), H1 2017 105

Products under Development by Companies, H1 2017 (Contd..15), H1 2017 106

Products under Development by Companies, H1 2017 (Contd..16), H1 2017 107

Products under Development by Companies, H1 2017 (Contd..17), H1 2017 108

Products under Development by Companies, H1 2017 (Contd..18), H1 2017 109

Products under Development by Companies, H1 2017 (Contd..19), H1 2017 110

Products under Development by Companies, H1 2017 (Contd..20), H1 2017 111

Products under Development by Companies, H1 2017 (Contd..21), H1 2017 112

Products under Development by Companies, H1 2017 (Contd..22), H1 2017 113

Products under Development by Companies, H1 2017 (Contd..23), H1 2017 114

Products under Development by Companies, H1 2017 (Contd..24), H1 2017 115

Products under Development by Companies, H1 2017 (Contd..25), H1 2017 116

Products under Development by Companies, H1 2017 (Contd..26), H1 2017 117

Products under Development by Universities/Institutes, H1 2017 118

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 119

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 120

Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017 121

Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017 122

Number of Products by Stage and Target, H1 2017 124

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 125

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 126

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 127

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017 128

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017 129

Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017 130

Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017 131

Number of Products by Stage and Mechanism of Action, H1 2017 133

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 134

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 135

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 136

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017 137

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017 138

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017 139

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017 140

Number of Products by Stage and Route of Administration, H1 2017 142

Number of Products by Stage and Molecule Type, H1 2017 144

Type 2 Diabetes Pipeline by 4P Therapeutics LLC, H1 2017 145

Type 2 Diabetes Pipeline by Addex Therapeutics Ltd, H1 2017 145

Type 2 Diabetes Pipeline by Adocia, H1 2017 146

Type 2 Diabetes Pipeline by Advinus Therapeutics Ltd, H1 2017 146

Type 2 Diabetes Pipeline by Aegis Therapeutics LLC, H1 2017 147

Type 2 Diabetes Pipeline by AFFiRiS AG, H1 2017 147

Type 2 Diabetes Pipeline by Alize Pharma SAS, H1 2017 148

Type 2 Diabetes Pipeline by Allergan Plc, H1 2017 148

Type 2 Diabetes Pipeline by Alteogen Inc, H1 2017 149

Type 2 Diabetes Pipeline by Amarantus Bioscience Holdings Inc, H1 2017 149

Type 2 Diabetes Pipeline by Amgen Inc, H1 2017 150

Type 2 Diabetes Pipeline by Anchor Therapeutics Inc, H1 2017 150

Type 2 Diabetes Pipeline by AntriaBio Inc, H1 2017 151

Type 2 Diabetes Pipeline by Aphios Corp, H1 2017 151

Type 2 Diabetes Pipeline by Araim Pharmaceuticals Inc, H1 2017 152

Type 2 Diabetes Pipeline by Arena Pharmaceuticals Inc, H1 2017 152

Type 2 Diabetes Pipeline by Arisaph Pharmaceuticals Inc, H1 2017 153

Type 2 Diabetes Pipeline by ArisGen SA, H1 2017 153

Type 2 Diabetes Pipeline by Astellas Pharma Inc, H1 2017 154

Type 2 Diabetes Pipeline by AstraZeneca Plc, H1 2017 155

Type 2 Diabetes Pipeline by AusBio Ltd, H1 2017 155

Type 2 Diabetes Pipeline by Avadel Pharmaceuticals Plc, H1 2017 156

Type 2 Diabetes Pipeline by Bayer AG, H1 2017 156

Type 2 Diabetes Pipeline by Beta-Cell NV, H1 2017 157

Type 2 Diabetes Pipeline by Betagenon AB, H1 2017 157

Type 2 Diabetes Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017 158

Type 2 Diabetes Pipeline by Biocon Ltd, H1 2017 158

Type 2 Diabetes Pipeline by BioLingus AG, H1 2017 159

Type 2 Diabetes Pipeline by BioRestorative Therapies Inc, H1 2017 159

Type 2 Diabetes Pipeline by Biozeus, H1 2017 160

Type 2 Diabetes Pipeline by Biscayne Pharmaceuticals Inc, H1 2017 160

Type 2 Diabetes Pipeline by Boehringer Ingelheim GmbH, H1 2017 161

Type 2 Diabetes Pipeline by Boston Therapeutics Inc, H1 2017 161

Type 2 Diabetes Pipeline by Braasch Biotech LLC, H1 2017 162

Type 2 Diabetes Pipeline by Bristol-Myers Squibb Company, H1 2017 162

Type 2 Diabetes Pipeline by C4X Discovery Holdings PLC, H1 2017 163

Type 2 Diabetes Pipeline by Cadila Pharmaceuticals Ltd, H1 2017 163

Type 2 Diabetes Pipeline by Cardax Inc, H1 2017 164

Type 2 Diabetes Pipeline by Carmot Therapeutics Inc, H1 2017 164

Type 2 Diabetes Pipeline by Celon Pharma SA, H1 2017 165

Type 2 Diabetes Pipeline by Chipscreen Biosciences Ltd, H1 2017 165

Type 2 Diabetes Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017 166

Type 2 Diabetes Pipeline by CJ HealthCare Corp, H1 2017 166

Type 2 Diabetes Pipeline by CohBar Inc, H1 2017 167

Type 2 Diabetes Pipeline by Concenter BioPharma Silkim Ltd, H1 2017 167

Type 2 Diabetes Pipeline by ConjuChem LLC, H1 2017 168

Type 2 Diabetes Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017 168

Type 2 Diabetes Pipeline by ConSynance Therapeutics Inc, H1 2017 169

Type 2 Diabetes Pipeline by Corium International Inc, H1 2017 169

Type 2 Diabetes Pipeline by CSL Ltd, H1 2017 170

Type 2 Diabetes Pipeline by CureDM Inc, H1 2017 170

Type 2 Diabetes Pipeline by CymaBay Therapeutics Inc, H1 2017 171

Type 2 Diabetes Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017 171

Type 2 Diabetes Pipeline by Daiichi Sankyo Company Ltd, H1 2017 172

Type 2 Diabetes Pipeline by Dance Biopharm Inc, H1 2017 172

Type 2 Diabetes Pipeline by Delpor Inc, H1 2017 173

Type 2 Diabetes Pipeline by Diabetology (Products) Ltd, H1 2017 173

Type 2 Diabetes Pipeline by DiaMedica Therapeutics Inc, H1 2017 174

Type 2 Diabetes Pipeline by Diamyd Medical AB, H1 2017 174

Type 2 Diabetes Pipeline by Diasome Pharmaceuticals Inc, H1 2017 175

Type 2 Diabetes Pipeline by DiscoveryBiomed Inc, H1 2017 175

Type 2 Diabetes Pipeline by DNJ Pharma Inc, H1 2017 176

Type 2 Diabetes Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017 176

Type 2 Diabetes Pipeline by Elcelyx Therapeutics Inc, H1 2017 177

Type 2 Diabetes Pipeline by Eli Lilly and Company, H1 2017 177

Type 2 Diabetes Pipeline by Enteris BioPharma Inc, H1 2017 178

Type 2 Diabetes Pipeline by Enzo Biochem Inc, H1 2017 178

Type 2 Diabetes Pipeline by Epichem Pty Ltd, H1 2017 179

Type 2 Diabetes Pipeline by Esperion Therapeutics Inc, H1 2017 179

Type 2 Diabetes Pipeline by Eternygen GmbH, H1 2017 180

Type 2 Diabetes Pipeline by Evotec AG, H1 2017 180

Type 2 Diabetes Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 181

Type 2 Diabetes Pipeline by Generex Biotechnology Corp, H1 2017 181

Type 2 Diabetes Pipeline by Genexine Inc, H1 2017 182

Type 2 Diabetes Pipeline by Genfit SA, H1 2017 182

Type 2 Diabetes Pipeline by Genmedica Therapeutics SL, H1 2017 183

Type 2 Diabetes Pipeline by Genovate Biotechnology Co LTD, H1 2017 183

Type 2 Diabetes Pipeline by Geropharm LLC, H1 2017 184

Type 2 Diabetes Pipeline by Gilead Sciences Inc, H1 2017 184

Type 2 Diabetes Pipeline by GlaxoSmithKline Plc, H1 2017 185

Type 2 Diabetes Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017 185

Type 2 Diabetes Pipeline by Glucox Biotech AB, H1 2017 186

Type 2 Diabetes Pipeline by GW Pharmaceuticals Plc, H1 2017 186

Type 2 Diabetes Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2017 187

Type 2 Diabetes Pipeline by HanAll Biopharma Co Ltd, H1 2017 187

Type 2 Diabetes Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017 188

Type 2 Diabetes Pipeline by Heptares Therapeutics Ltd, H1 2017 188

Type 2 Diabetes Pipeline by HitGen LTD, H1 2017 189

Type 2 Diabetes Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017 189

Type 2 Diabetes Pipeline by Immuron Ltd, H1 2017 190

Type 2 Diabetes Pipeline by Innopharmax Inc, H1 2017 190

Type 2 Diabetes Pipeline by Innovative Targeting Solutions Inc, H1 2017 191

Type 2 Diabetes Pipeline by Intarcia Therapeutics Inc, H1 2017 191

Type 2 Diabetes Pipeline by Intas Pharmaceuticals Ltd, H1 2017 192

Type 2 Diabetes Pipeline by Integral Molecular Inc, H1 2017 192

Type 2 Diabetes Pipeline by Intercept Pharmaceuticals Inc, H1 2017 193

Type 2 Diabetes Pipeline by Intrexon Corp, H1 2017 193

Type 2 Diabetes Pipeline by Ionis Pharmaceuticals Inc, H1 2017 194

Type 2 Diabetes Pipeline by Ironwood Pharmaceuticals Inc, H1 2017 194

Type 2 Diabetes Pipeline by Islet Sciences Inc, H1 2017 195

Type 2 Diabetes Pipeline by Japan Tobacco Inc, H1 2017 195

Type 2 Diabetes Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017 196

Type 2 Diabetes Pipeline by Jenrin Discovery Inc, H1 2017 196

Type 2 Diabetes Pipeline by JHL Biotech Inc, H1 2017 197

Type 2 Diabetes Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017 197

Type 2 Diabetes Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 198

Type 2 Diabetes Pipeline by Johnson & Johnson, H1 2017 199

Type 2 Diabetes Pipeline by Kadimastem Ltd, H1 2017 200

Type 2 Diabetes Pipeline by Kadmon Corp LLC, H1 2017 200

Type 2 Diabetes Pipeline by Kareus Therapeutics SA, H1 2017 201

Type 2 Diabetes Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017 201

Type 2 Diabetes Pipeline by Lead Discovery Center GmbH, H1 2017 202

Type 2 Diabetes Pipeline by Leading BioSciences Inc, H1 2017 202

Type 2 Diabetes Pipeline by Lexicon Pharmaceuticals Inc, H1 2017 203

Type 2 Diabetes Pipeline by LG Chem, Ltd., H1 2017 203

Type 2 Diabetes Pipeline by Ligand Pharmaceuticals Inc, H1 2017 204

List of Figures

List of Figures

Number of Products under Development for Type 2 Diabetes, H1 2017 69

Number of Products under Development by Companies, H1 2017 70

Number of Products under Development by Universities/Institutes, H1 2017 86

Number of Products by Top 10 Targets, H1 2017 123

Number of Products by Stage and Top 10 Targets, H1 2017 123

Number of Products by Top 10 Mechanism of Actions, H1 2017 132

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 132

Number of Products by Top 10 Routes of Administration, H1 2017 141

Number of Products by Stage and Top 10 Routes of Administration, H1 2017 141

Number of Products by Top 10 Molecule Types, H1 2017 143

Number of Products by Stage and Top 10 Molecule Types, H1 2017 143

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports